CytoSorbents Expands Distribution to 53 Countries

On Jul 31, 2018

Monmouth Junction-based CytoSorbents Corporation, a critical care immunotherapy leader has expanded the distribution of CytoSorb® to a total of 53 countries worldwide. The company is using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world.

Recently added countries (and distributors), accounting for an additional 31 million people, include:

• Lebanon – Pharma World LB
• Bosnia, Herzegovina, and Croatia – Medis, d.o.o.
• Estonia, Latvia, and Lithuania – SIA Scanmed
• Moldova – Smart Medical Solutions
• Montenegro and Serbia – Mar Medica, d.o.o.

The Company also announced the change of the company’s distributor in the United Kingdom to Chalice Medical Ltd., with a focus on England and Ireland.

Dr. Christian Steiner, Senior Vice President of Sales and Marketing of CytoSorbents Corporation stated, “There is continued strong interest among clinicians and researchers from many countries around the world who have heard or learned about our CytoSorb therapy from international congresses and colleagues.  They are hearing the positive experiences and are seeing the clinical data on how CytoSorb is helping to control deadly inflammation in critically-ill and cardiac surgery patients. We are pleased to expand the global footprint of CytoSorb and to partner with these exceptional medical distributors to make CytoSorb available to all patients in need, wherever and whenever possible.”

To access more business news, visit NJB News Now.

Related Articles: